Protocol Ledger

NCT05561387 · Phase III · RECRUITING

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Interventional Phase III clinical trial protocol NCT05561387 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-12 Enrollment: 510 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05561387
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)510 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05561387
Protocol FieldVerified Registry Value
NCT IdentifierNCT05561387
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment510 participants (ESTIMATED)
Registered Start Date2023-10-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI